Clinical trials: Autoimmune State
Autism Spectrum Disorder, Autism
Autism Spectrum Disorder (ASD) Neurodevelopmental Disorder With Issues Social Behavior, Communication Issues, GI Dysfunction. Study is Multimodal Interventions Targeting These Pathways With cSVF, Stored MSCs, FMT and Diet Modification. Role of Autoimmunity, Gut-brain Issues, & Issues Examined.
Autism spectrum disorder (ASD) is a neurodevelopmental condition with core deficits in social communication and behavior, often accompanied by gastrointestinal (GI) and metabolic dysfunction.
- Conditions
- Autism Spectrum Disorder, Autism, Autism Spectral Disorder
- Trial name
- GARM-Autism (NCT07546942)
- Testing
- Autologous MSC isolation, concentration, and cryopreservation of adult mesenchymal stem cells, Fecal Biomicrome Transplantation (FMT), Ketogenic RESET Diet Protocol
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Black Tie Medical, Inc.
Diabetes, Diabetes Mellitus, Type 1
Comparison of Insulin Degludec With Insulin Glargine in Subjects With Type 1 Diabetes Mellitus
This trial was conducted in Europe. The aim of this trial was to compare the pharmacodynamic (the effect of the investigated drug on the body) response of insulin degludec (insulin 454) with insulin glargine at steady-state…
- Trial name
- NCT01868529
- Testing
- insulin degludec, insulin glargine
- Where
- Germany
- Volunteers
- 63 people
- Sponsor
- Novo Nordisk A/S
Systemic Lupus Erythematosus
A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE
The purpose of this study is to assess whether co-administration of belimumab and a single cycle of rituximab will optimize treatment with belimumab, which will result in improvements of clinical status with a favorable safety…
- Trial name
- NCT03312907
- Testing
- Belimumab, Rituximab, Standard therapy (Including Immunosuppressants)
- Where
- 79 sites in United States, Argentina and 9 more
- Volunteers
- 292 people
- Sponsor
- GlaxoSmithKline
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of this clinical trial is to evaluate the variability in the blood glucose-lowering effect of NN1250 (insulin degludec) in subjects with type 1 diabetes.
- Trial name
- NCT00961324
- Testing
- insulin degludec, insulin glargine
- Where
- Germany
- Volunteers
- 54 people
- Sponsor
- Novo Nordisk A/S
Multiple Sclerosis
31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis.
REPAIR-MS is a single-center open label, sequential group, investigator and patient blinded study to assess the CNS metabolic effects, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in patients who have been diagnosed…
- Trial name
- REPAIR-MS (NCT03993171)
- Testing
- gold nanocrystals
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Clene Nanomedicine
Diabetes Mellitus, Type 1
Diabetes AutoimmunitY Withdrawn in Established Patients (DAY)
The study is a prospective, randomized, double-blind, placebo-controlled, multicenter trial in subjects with established T1D.
- Trial name
- DAY (NCT03794960)
- Testing
- TOL-3021
- Sponsor
- Tolerion, Inc.
Diabetes, Diabetes Mellitus, Type 1
Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus
This trial is conducted in Europe. The aim of this trial is to compare pharmacodynamic (the effect of the investigated drug on the body) and pharmacokinetic (the exposure of the trial drug in the body) properties of insulin…
- Trial name
- NCT02536859
- Testing
- insulin degludec, insulin glargine
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Diabetes Autoimmunity Withdrawn in New Onset Patients (DAWN)
The study is a prospective, randomized, double-blind, placebo-controlled, multi-center trial in subjects with new onset T1D.
- Trial name
- DAWN (NCT03794973)
- Testing
- TOL-3021
- Where
- United States
- Sponsor
- Tolerion, Inc.
Sjögren's Syndrome (SS)
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
Primary Objective: To evaluate the effect of dazodalibep on patient-reported symptoms of SS in participants with moderate-to-severe symptom state Secondary Objectives: 1.
- Trial name
- NCT06245408
- Testing
- Dazodalibep
- Where
- 194 sites in United States, Argentina and 24 more
- Volunteers
- 434 people
- Sponsor
- Amgen
Diabetes, Diabetes Mellitus, Type 1
Pharmacokinetics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate steady state pharmacokinetics of biphasic insulin aspart 30 and biphasic insulin aspart 70 in subjects with type 1 diabetes.
- Trial name
- NCT01524809
- Testing
- biphasic insulin aspart 30, biphasic insulin aspart 70
- Where
- Denmark
- Volunteers
- 26 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
A Trial Evaluating the Effect of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes
This trial was conducted in Europe. The aim of this clinical trial was to evaluate the effect on the blood glucose-lowering effect of NN1250 (insulin degludec) in subjects with type 1 diabetes.
- Trial name
- NCT01114542
- Testing
- insulin degludec, insulin glargine
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- Novo Nordisk A/S
Latent Autoimmune Diabetes in Adult (LADA)
Safety of Diamyd® in Patients With LADA (Latent Autoimmune Diabetes in Adult)
This is a study to investigate the safety of 20ug Diamyd® (rhGAD65 formulated in Alhydrogel®), administered subcutaneously four weeks apart in patients with Latent Autoimmune Diabetes in Adult (LADA).
- Trial name
- NCT00456027
- Testing
- rhGAD65 formulated in Alhydrogel® (Diamyd®)
- Where
- 17 sites in Sweden
- Volunteers
- 160 people
- Sponsor
- Diamyd Therapeutics AB
Rheumatoid Arthritis
Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)
The purpose of this study is to study serum levels of Abatacept after subcutaneous dosing in subjects with RA.
- Trial name
- NCT00254293
- Testing
- Abatacept
- Where
- 5 sites in United States
- Volunteers
- 87 people
- Sponsor
- Bristol-Myers Squibb
Healthy, Prediabetic State (IGT)
Noninvasive Transcutaneous Glucometer Development
The objective of this study is to assist in the development of a noninvasive device for the accurate measurement of blood glucose levels.
- Conditions
- Healthy, Prediabetic State (IGT), Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
- Trial name
- NCT01168076
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- InLight Solutions
Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
The purpose of this study is to evaluate the safety and tolerability of ATA188 as a monotherapy in Parts 1 and 2, to determine the recommended Part 2 dose (RP2D) of ATA188 as monotherapy in Part 1, and to evaluate the effect of…
- Trial name
- EMBOLD (NCT03283826)
- Testing
- ATA188
- Where
- 31 sites in United States, Australia and 1 more
- Volunteers
- 134 people
- Sponsor
- Atara Biotherapeutics
Diabetes Mellitus, Type 1
A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week
This study compares the new long-acting insulin 287 with the marketed insulin glargine for use in type 1 diabetes. The study will test how insulin is taken up in your blood, how long it stays there and how the blood sugar is…
- Trial name
- NCT03723772
- Testing
- Insulin icodec, IGlar U100
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
To Evaluate the Bioavailability of a Tablet of AZD1656
To evaluate the bioavailability of a tablet of AZD1656.
- Trial name
- NCT00817505
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- AstraZeneca
Endometriosis
Open Label Immunotherapy of Endometriosis
Endometriosis is a chronic gynecological disease characterized by sustained painful symptoms that are responsible for a decline in the quality of life of sufferers.
- Trial name
- NCT03340324
- Testing
- V-Endo
- Where
- Mongolia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Immunitor LLC
Type 1 Diabetes
Efficacy and Safety of Diamyd® in Children and Adolescents With Type 1 Diabetes
This is a randomized, placebo-controlled phase II study to investigate if a prime and boost of 20ug Diamyd® (rhGAD65 formulated in Alhydrogel®), administered subcutaneously four weeks apart, is safe and can preserve beta cell…
- Trial name
- NCT00435981
- Testing
- rhGAD65 formulated in Alhydrogel® (Diamyd®)
- Where
- 8 sites in Sweden
- Volunteers
- 70 people
- Sponsor
- Diamyd Therapeutics AB
Type 1 Diabetes
Reversal of Type 1 Diabetes in Children by Stem Cell Educator Therapy
Type 1 diabetes (T1D) is an autoimmune disease that usually occurs in children and reduces their pancreatic islet beta cells and thereby limits insulin production.
- Trial name
- NCT01996228
- Testing
- Stem Cell Educator
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Throne Biotechnologies Inc.